Shilpa Medicare gets USFDA nod for Gemcitabine to treat types of cancer
The company has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection USP in the strengths of 200 mg/vial and 1 g/vial, Shilpa Medicare said in a BSE filing.
New Delhi: Shilpa Medicare on Monday said it has received approval from the US health regulator for Gemcitabine for injection, used for the treatment of various types of cancers. The approved product is a generic equivalent of reference listed drug Gemzar.
The company has received US Food and Drug Administration (USFDA) approval for its Abbreviated New Drug Application (ANDA), Gemcitabine for injection USP in the strengths of 200 mg/vial and 1 g/vial, Shilpa Medicare said in a BSE filing.
Read Also: Shilpa Medicare gets tentative USFDA nod for Dimethyl Fumarate delayed release capsules
Gemcitabine for injection USP is used in the treatment of ovarian cancer, breast cancer, non-small cell lung cancer and pancreatic cancer.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd